MapLight starts set-up of confirmatory Phase 3 ZEPHYR-2 in schizophrenia
The US biotech reported Q3 results on 16 November 2026, with cash of $463.4 million, and said Alzheimer's psychosis data from VISTA are now expected in 2028.
MapLight Therapeutics published its third-quarter results and a business update on 16 November 2026. The company said it has begun start-up activities for ZEPHYR-2, a confirmatory Phase 3 trial of ML-007C-MA in schizophrenia. It also plans to hold an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA). The title of the release puts cash at $463.4 million at the end of the third quarter.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): MapLight Therapeutics, Inc. ↗
Article written by VigiEye from the official source (MapLight Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.